Skip to main content
. 2022 May 29;14(6):1160. doi: 10.3390/pharmaceutics14061160

Figure 13.

Figure 13

Impact of Ap or Ap-CH-BSA-FANPs treatment on SOD and CAT activities in HePG-2 cells. * Shows significant difference (p ≤ 0.01) compared with the untreated HePG-2.